A publication from Acta Pharmaceutica Sinica B discusses the structure-based development of potent and selective type-II kinase inhibitors of RIPK1. Receptor-interacting serine/threonine-protein ...

Researchers provide essential insights on the molecular activation of the MAP kinase p38?, the final switch triggering the inflammatory response. Inflammation is a cellular coping mechanism when ...

To design drugs that stall the growth of aggressive cancers, it helps to know the structures of the proteins that are revving the cancers' engines. In a series of three papers published in Proceedings ...

Protein kinases, including p38α, have therefore been heavily studied. The first protein kinase structure was solved 30 years ago – a landmark in the field – and many more structures have followed, ...